Merger Notification - Announcement according to § 10 Cartel Act
ArchiMed SAS; Ark Diagnostics, Inc.
BWB/Z-7076
On 19.09.2025 the Austrian Federal Competition Authority was notified of the following merger:
Planned purchase process
ArchiMed SAS, France, intends to acquire 60% of shares in and sole control over Ark Diagnostics, Inc., United States, which is currently wholly owned by Soulbrain Holdings Co., Ltd, Korea.
C - MANUFACTURING C 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations, C 21.2 - Manufacture of pharmaceutical preparations, C 21.20 - Manufacture of pharmaceutical preparations
Deadline for bringing in an application pursuant to § 11(1) Cartel Act will end on 17.10.2025.
Entrepreneurs whose legal or economic interests are affected by the merger can bring in a written statement at the Federal Competition Authority or the Federal Cartel Prosecutor within 14 days from publication date.
Note: The intervening party has no right to a certain treatment of the statement and will not gain a party position.
Non-prohibition of the merger
The Federal Competition Authority and the Federal Cartel Prosecutor have not applied for examination of the merger by the Cartel Court. The standstill obligation (§ 17 (1) Cartel Act) ends with effect from 18.10.2025 .